论文部分内容阅读
新形势下的新组合 宝依普公司是在经济科技体制改革、新的经济体制形成的新形势下成立起来的股份制企业,其前身是海南亚龙生物医学研究所。 海南亚龙实业总公司下属的海南亚龙生物医学研究所自1992年起开始开发rhEPO项目,该项目是基因工程药物领域最具临床前景的项目之一,年销售额十多亿美元,1992年被排名世界第七位畅销药。在前期科研资金不足、设备条件差的状态下公司科技人员克服困难,创造条件,硬是把握住机遇,完成了rhEPO项目的上游研究工作。其后,与南京军区后勤军事医学研究所一起成功地完成了rhEPO项目的临床前研究工作,并于1994年2月获得了卫生部药政局批准该药进入临床试验的批文。这项成果的建立在生物技术领域引起了轰动,
The new combination under the new situation Bao Yipu Co., Ltd. is a joint-stock company established under the new situation of economic and technological system reform and the formation of a new economic system. Its predecessor was Hainan Yalong Institute of Biomedical Research. The Hainan Yalong Biomedical Research Institute of Hainan Yalong Industry Corporation has been developing the rhEPO project since 1992. This project is one of the most clinically promising projects in the field of genetic engineering drugs, with annual sales of more than one billion US dollars, 1992. Ranked seventh best-selling drug in the world. Under the condition of insufficient scientific research funds and poor equipment conditions in the early stage, the company’s scientific and technical personnel overcome difficulties and create conditions, and simply seized the opportunity to complete the upstream research work on the rhEPO project. Subsequently, the pre-clinical research work on the rhEPO project was successfully completed with the Military Medical Research Institute of the Nanjing Military Region. In February 1994, the Ministry of Health’s Bureau of Pharmacy approved the drug’s approval for clinical trials. The establishment of this result caused a sensation in the field of biotechnology.